MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the year ending 2025-12-31.

Cash Flow Overview

Free Cash flow
-$112,037K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of investments
    • Depreciation and amortization
    • Interest income
    • Others
Negative Cash Flow Breakdown
    • Purchases of investments
    • Accounts payable and accrued exp...
    • Purchases of property and equipm...
    • Others

Cash Flow
2025-12-31
Collaboration revenue
6,646
Total operating expenses
154,350
Loss from operations
-147,704
Interest income
11,052
Change in fair value of stock price appreciation milestones
-244
Other income
93
Total other income
11,389
Net loss
-136,315
Depreciation and amortization
12,901
Stock-based compensation
24,924
Accretion and amortization of premiums and discounts on investments, net
3,606
Deferred revenue
-12
Changes in fair value of stock price appreciation milestones
-244
Impairment of long-lived assets
0
Loss on disposal of property and equipment
-9
Accounts receivable
-2,624
Prepaid expenses and other assets
-5,179
Accounts payable and accrued expenses
-9,027
Right-of-use assets and lease liabilities, net
-2,517
Net cash used in operating activities
-106,084
Proceeds from sale of property and equipment
362
Purchases of property and equipment
5,953
Purchases of investments
195,143
Maturities of investments
311,900
Net cash provided by investing activities
111,166
Issuance of common stock from equity incentive plans, net of issuance costs
0
Proceeds from public offering of common stock, net of issuance costs
0
Proceeds from issuance of pre-funded warrants, net of issuance costs
0
Proceeds from ft819 cirm award
1,490
Proceeds from ft836 cirm award
-4,000
Net cash provided by financing activities
5,490
Net change in cash, cash equivalents and restricted cash
10,572
Cash, cash equivalents and restricted cash at beginning of the year
46,283
Cash, cash equivalents and restricted cash at end of the year
56,855
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of investments$311,900K Proceeds from ft836 cirmaward-$4,000K Proceeds from ft819 cirmaward$1,490K Proceeds from sale ofproperty and equipment$362K Net cash provided byinvesting activities$111,166K Net cash provided byfinancing activities$5,490K Canceled cashflow$201,096K Net change in cash,cash equivalents and...$10,572K Canceled cashflow$106,084K Purchases of investments$195,143K Purchases of property andequipment$5,953K Stock-based compensation$24,924K Depreciation andamortization$12,901K Prepaid expenses andother assets-$5,179K Accounts receivable-$2,624K Loss on disposal ofproperty and equipment-$9K Interest income$11,052K Change in fair value ofstock price...-$244K Other income$93K Net cash used inoperating activities-$106,084K Canceled cashflow$45,637K Total other income$11,389K Net loss-$136,315K Canceled cashflow$11,389K Accounts payable andaccrued expenses-$9,027K Accretion andamortization of premiums and...$3,606K Right-of-use assets and leaseliabilities, net-$2,517K Changes in fair value ofstock price...-$244K Deferred revenue-$12K Collaboration revenue$6,646K Loss from operations-$147,704K Canceled cashflow$6,646K Total operatingexpenses$154,350K

FATE THERAPEUTICS INC (FATE)

FATE THERAPEUTICS INC (FATE)